Printer Friendly

SYNCOR ANNOUNCES RECORD SECOND QUARTER, SIX MONTH RESULTS

 SYNCOR ANNOUNCES RECORD SECOND QUARTER, SIX MONTH RESULTS
 CHATSWORTH, Calif., Dec. 16 /PRNewswire/ -- Syncor International Corporation (NASDAQ: SCOR) announced today record sales and earnings for the second quarter and the six month period ended Nov. 30, 1991. This is the tenth consecutive quarter that the company has achieved record sales and earnings.
 Sales in the second quarter of fiscal 1992 increased 36 percent to a record $50.6 million, up from $37.3 million in the second quarter of fiscal 1991. Sales for the six month period ended Nov. 30, 1991, increased 34 percent to a record $98 million, as compared to $73.3 million for the corresponding period of the prior year. Net income for the second quarter of fiscal 1992 increased 47 percent to $1.5 million, or $0.14 per share compared with $1.0 million or $0.10 per share for fiscal 1991. Net income for the six months ended Nov. 30, 1991, increased 49 percent to $3.1 million or $0.29 per share, up from $2.1 million or $0.21 per share for the same period in fiscal 1991.
 Commenting on the record sales and earnings, Gene McGrevin, Syncor's president and chief executive officer, stated, "We are continuing to experience sales gains in the cardiac imaging market. The growth is being fueled by the excellent reception of DuPont Merck's "Cardiolite(R)" and "I.V. Persantine(R)" (manufactured and distributed by DuPont Merck under license from Boehringer Ingleheim Pharmaceuticals). Demand for Thallium, a competing heart agent, also marketed by Syncor, remains strong. To ensure that all these products achieve future market penetration gains, we will continue to invest in marketing and sales resources."
 Syncor International operates an expanded nationwide network of 90 nuclear pharmacy service centers and 14 home care pharmacies. The company prepares and delivers patient specific intravenous drugs and solutions for use in diagnostic imaging and a complete range of products for home infusion therapy. Syncor services over 5,000 hospitals, clinics, physicians' offices, nursing facilities, and home-based patients. Syncor is the only national pharmacy network of its kind that provides this combination of diagnostic, therapeutic, and monitoring services to hospitals and alternate site markets.
 SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
 Consolidated Statement of Operations
 (Unaudited, in thousands, except per share data)
 Periods ended Three months Six months
 Nov. 30: 1991 1990 1991 1990
 Net sales $50,587 $37,322 $97,919 $73,346
 Cost of sales 32,889 24,198 63,342 47,722
 Gross profit 17,698 13,124 34,577 25,624
 Operating, selling and
 administrative expenses 15,138 11,303 29,316 21,997
 Operating income 2,560 1,821 5,261 3,627
 Other income
 (expense), net 15 (103) 46 (129)
 Income before provision
 for taxes 2,575 1,718 5,307 3,498
 Provision for taxes 1,057 688 2,178 1,401
 Net income 1,518 1,030 3,129 2,097
 Net inc. per share of
 common stock & common
 stock equivalents $0.14 $0.10 $0.29 $0.21
 Weighted avg. common
 stock & common stock
 equivalents 10,848 10,156 10,761 10,027
 -0- 12/16/91
 /CONTACT: Michael E. Mikity, vice president-finance of Syncor, 818-886-7400, or Susan Noonan or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Syncor/
 (SCOR) CO: Syncor International Corporation ST: California IN: MTC SU: ERN


TS-MA -- NY006 -- 2352 12/16/91 08:32 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1991
Words:566
Previous Article:SILICON GRAPHICS LAUNCHES IRIS PARTNERS PROGRAM
Next Article:BUTTERBALL TURKEY KEEPS TALK-LINE OPEN TILL CHRISTMAS
Topics:


Related Articles
SYNCOR ANNOUNCES RECORD THIRD QUARTER AND NINE MONTH RESULTS
SYNCOR ANNOUNCES RECORD FOURTH QUARTER AND YEAR END RESULTS
SYNCOR ANNOUNCES RECORD FIRST QUARTER RESULTS
SYNCOR ANNOUNCES RECORD SECOND QUARTER AND SIX MONTH RESULTS
SYNCOR WINS CONTRACTS TO PROVIDE RADIOPHARMACEUTICAL SERVICES TO AMERINET AND GALEN HEALTH CARE
SYNCOR SIGNS LETTER OF INTENT TO SELL HOME INFUSION BUSINESS; W.R. GRACE & CO. TO PURCHASE EIGHT HOME CARE SITES
CARDINAL HEALTH NET UP 28% IN 3RD QUARTER.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters